A Phase 2 Randomized Open-Label Active Controlled Study

Recruiting

99 years or below

All

1 Location

Brief description of study

This is a Phase 2, randomized, open-label, active-controlled, multicenter study to evaluate the safety, efficacy, and PK of ISL + LEN. The target population is virologically suppressed people living with HIV (PWH) who are at least 18 years of age and meet other study inclusion criteria. All participants will be randomized to Cohort 2, in a 1:1 ratio to receive either oral LEN + ISL or B/F/TAF (Biktarvy).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 14 Jun 2023. Study ID: 853343

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase 2 Randomized Open-Label Active Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination with Lenacapavir in Virologically Suppressed People with HIV

Brief description of study

Eligibility of study

Find a site

Interested in the study